Lorcainide for the Treatment of Refractory Ventricular Tachycardia: Clinical and Electrophysiologic Results

James Hanyok(Daiichi Sankyo (United States)), Arnold Fieldman(Hartford Hospital), Moses S.S. Chow(Hartford Hospital), Jeffrey Kluger(Hartford Hospital)
The Journal of Clinical Pharmacology
April 1, 1987
10.1002/j.1552-4604.1987.tb03013.x
Cited by 2

Related Papers

Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
|American Heart Journal|2010|482
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
|New England Journal of Medicine|2006|397
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
|American Heart Journal|1995|121